General Information of Drug (ID: DM4X0WY)

Drug Name
N-Omega-Propyl-L-Arginine Drug Info
Synonyms
N-OMEGA-PROPYL-L-ARGININE; 137361-05-8; omega-propyl-l-arginine; CHEMBL107528; (S)-2-Amino-5-(3-propylguanidino)pentanoic acid; Nomega-Propyl-L-arginine hydrochloride; (2S)-2-amino-5-[(N'-propylcarbamimidoyl)amino]pentanoic acid; Nomega-Propyl-L-arginine; hDDAH inhibitor, 2b; Tocris-1200; NCGC00025034-01; Nomegapropyl-L-arginine; N- -Propyl-L-Arginine; 3AR; 2-amino-5-[(N'-propylcarbamimidoyl)amino]pentanoic acid; AC1L9KK0; N.omega.-propyl-L-Arginine; GTPL6525; SCHEMBL1004634; CTK8E7922; DTXSID30332245; MolPort-006-395-775
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
447180
CAS Number
CAS 137361-05-8
TTD Drug ID
DM4X0WY

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Curcumin DMQPH29 Solid tumour/cancer 2A00-2F9Z Phase 3 [3]
SD-6010 DM9DEYL Osteoarthritis FA00-FA05 Phase 3 [4]
MPL-S DMNDCFY Endotoxic shock 1G41 Phase 3 [5]
Pimagedine HCl DMPWH30 Diabetic kidney disease GB61.Z Phase 2/3 [6]
GW274150 DMZMCB1 Asthma CA23 Phase 2 [7]
BXT-51072 DMD8GNB Cardiovascular disease BA00-BE2Z Phase 2 [8]
HP-228 DMNZ35F Postoperative pain MG30-MG3Z Phase 2 [9]
CR-3294 DMHJEZS Diarrhea ME05.1 Phase 2 [10]
KD-7040 DME1WV2 Pain MG30-MG3Z Phase 2 [11]
LT-1951 DM5N04G Coronary artery disease BA80 Phase 1/2 [12]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
NXN-188 DMMBAIH Migraine 8A80 Phase 2 [13]
NXN-462 DMWVBS2 Headache 8A80-8A84 Phase 2 [14]
L-NIL DM6Y49D N. A. N. A. Terminated [15]
Alpha-D-Mannose DMF5DLW Discovery agent N.A. Investigative [2]
Acetate Ion DMD08RH Discovery agent N.A. Investigative [2]
Flavin-Adenine Dinucleotide DM5S4GK Discovery agent N.A. Investigative [2]
Heme DMGC287 Discovery agent N.A. Investigative [16]
Formic Acid DMNFZC6 Discovery agent N.A. Investigative [2]
2'-Monophosphoadenosine 5'-Diphosphoribose DME9S8M Discovery agent N.A. Investigative [2]
6-isobutyl-4-methylpyridin-2-amine DM2XB68 Discovery agent N.A. Investigative [17]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Nitric-oxide synthase brain (NOS1) TTZUFI5 NOS1_HUMAN Inhibitor [2]
Nitric-oxide synthase inducible (NOS2) TTF10I9 NOS2_HUMAN Inhibitor [2]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6525).
2 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
3 A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8.
4 A 2-year randomised, double-blind, placebo-controlled, multicentre study of oral selective iNOS inhibitor, cindunistat (SD-6010), in patients with symptomatic osteoarthritis of the knee. Ann Rheum Dis. 2013 Feb;72(2):187-95.
5 Lipopolysaccharide and monophosphoryl lipid A differentially regulate interleukin-12, gamma interferon, and interleukin-10 mRNA production in murine macrophages. Infect Immun. 1997 Aug;65(8):3239-47.
6 Nitric oxide associated with iNOS expression inhibits acetylcholinesterase activity and induces memory impairment during acute hypobaric hypoxia. Brain Res. 2008 Sep 16;1230:138-49.
7 GW274150, a potent and highly selective inhibitor of iNOS, reduces experimental renal ischemia/reperfusion injury. Kidney Int. 2003 Mar;63(3):853-65.
8 Shear stress induces iNOS expression in cultured smooth muscle cells: role of oxidative stress. Am J Physiol Cell Physiol. 2000 Dec;279(6):C1880-8.
9 HP-228, a novel synthetic peptide, inhibits the induction of nitric oxide synthase in vivo but not in vitro. J Pharmacol Exp Ther. 1995 Nov;275(2):584-91.
10 Efficacy of CR3294, a new benzamidine derivative, in the prevention of 5-fluorouracil-induced gastrointestinal mucositis and diarrhea in mice. Cancer Chemother Pharmacol. 2010 October; 66(5): 819-827.
11 WO patent application no. 2014,0214,08, Method for treating cancer by anticancer agent co-administration.
12 Critical role of L-arginine in endothelial cell survival during oxidative stress. Circulation. 2003 May 27;107(20):2607-14.
13 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
14 ClinicalTrials.gov (NCT01748877) Efficacy, Tolerability, and Safety of NXN-462 in Patients With Post-Herpetic Neuralgia. U.S. National Institutes of Health.
15 Discovery of a series of aminopiperidines as novel iNOS inhibitors. Bioorg Med Chem Lett. 2008 Jan 1;18(1):336-43.
16 The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17 Design and synthesis of 2-amino-4-methylpyridine analogues as inhibitors for inducible nitric oxide synthase and in vivo evaluation of [18F]6-(2-fl... J Med Chem. 2009 Apr 23;52(8):2443-53.